Current Status of the Utilization of Antiepileptic Treatments in Mood, Anxiety and Aggression: Drugs and Devices

Clinical EEG and Neuroscience

Volumn 35, Issue 1, 2004, Pages 4-13

  Barry, John J ^a   Lembke, Anna ^a   Bullock, Kim D ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aggressive Disorders; Bipolar Affective Disorder; Obsessive Compulsive Disorder; Panic Disorder; Post traumatic Stress Disorder; Social Phobia; Transcranial Magnetic Stimulation; Vagus Nerve Stimulation

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AGGRESSION; ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; DEVICE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SOCIAL PHOBIA; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

AGGRESSION; ANTICONVULSANTS; ANXIETY DISORDERS; COMBINED MODALITY THERAPY; DRUG RESISTANCE; DRUG UTILIZATION; ELECTRIC STIMULATION THERAPY; HUMANS; MAGNETICS; MOOD DISORDERS;

EID: 1842429173     PISSN: 15500594     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940403500107     Document Type: Article

References (103)

1. Ketter TA Manji HK Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23: 484-495.
2. Boylan LS Devinsky O Barry JJ, et al. Psychiatric uses of antiepileptic treatments. Epilepsy Behav 2002; 3: S54-S59.
3. Bowden CL. Treatment of bipolar disorder. In: Schatzberg AF, Nemeroff CB, (eds). Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, Inc.; 1998: 733-746.
4. Ketter TA Post RM Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53: S53-S67.
5. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 1994.
6. Kessler RC Berglund P Dernier O Jin R Koretz D Merikangas KR, et al. The epidemiology of Major Depressive Disorder, results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095-3105.
7. Schatzberg AF. Bipolar disorder: Recent issues in diagnosis and classification. J Clin Psychiatry 1998; 59(6): 5-10.
8. Kessler RC McGonagle KA Shanyang Z, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch Gen Psychiatry 1994; 51: 8-19.
9. McElroy SL Keck PE. Diagnosis and treatment of rapid cycling states in bipolar disorder. In: Yatham LN, Kusumaker V, Kutcher SP, (eds). Bipolar Disorder, A Clinicians Guild To Biological Treatments. New York: Brunner-Routledge; 2002; 33-57.
10. Charney DS Berman RM Miller HL. Treatment of depression. In: Schatzberg AF, Nemeroff CB, (eds). Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press, Inc.; 1998; 705-732.
11. Calabrese JR Shelton MD Rapport DJ, et al. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord 2001; 67(1-3): 241-255.
12. MacRitchie K Geddes JR Scott J, et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; 1: 1-48.
13. Frye MA Altshuler LL Szuba MP, et al. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry 1996; 57: 17-21.
14. Suppes T Dennehy EB Swann AC, et al. Texas Consensus Conference Panel on Medication Treatment of Bipolar D: Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002; 63(4): 288-299.
15. Keck PE Jr Mendlwicz J Calabrese JR, et al. A review of randomized, controlled clinical trials in acute mania. J Affect Disord 2000; 59(suppl) 1: S31-S37.
16. Keck PE Jr McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry 2002; 63(suppl 10): 13-17.
17. Yatham LN Kusumakar V. Anticonvulsants in treatment of bipolar disorder: A review of efficacy. In: Yatham LN, Kusumaker V, Kutcher SP, (eds). Bipolar Disorder: A Clinicians Guild To Biological Treatments. New York: Brunner-Routledge; 2002: 201-240.
18. Lerer B Moore N Meyendorff E, et al. Carbamazepine versus lithium in mania: A double-blind study. J Clin Psychiatry 1987; 48(3): 89-93.
19. Emrich HM Altmann H Dose M, et al. Therapeutic effects of GABA-ergic drugs in affective disorders: A preliminary report. Pharmacol Biochem Behavior 1983; 19(2): 369-372.
20. Emrich HM Dose M von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8(3): 243-250.
21. Mishory A Yaroslavsky Y Bersudsky Y, et al. Phenytoin as an antimanic anticonvulsant: A controlled study. Am J Psychiatry 2000; 157(3): 463-465.
22. Pande AC Crockatt JG Janney CA, et al. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2(3 Pt 2): 249-255.
23. Frye MA Ketter TA Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20(6): 607-614.
24. Yatham LN Kusumakar V Calabrese JR, et al. Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002; 63(4): 275-283.
25. Erfurth A Grunze H. New perspectives in the treatment of acute mania: A single case report. Prog Neuro-Psychopharmacol Biol Psychiatry 1998; 22(6): 1053-1059.
26. Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Euro Neuropsychopharmacology 1999; 9(suppl) 4: S119-S123.
27. Ichim L Berk M Brook S. Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial. Ann Clin Psychiatry 2000; 12(1): 5-10.
28. Anand A Oren DA Berman R, et al. Lamotrigine treatment of lithium failure outpatient mania: a double blind placebo controlled trial. In: Soares J, Gershon S,(eds). 3rd International Conference on Bipolar Disorder; Pittsburgh, PA; 1999: 23.
29. Grunze HC Normann C Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62(6): 464-468.
30. Normann C Langosch J Schaerer LO, et al. Treatment of acute mania with topiramate. Am J Psychiatry 1999; 156(12): 2014.
31. Pecuch PW Erfurth A. Topiramate in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(2): 243-244.
32. Grunze H Erfurth A Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11): 759-762.
33. Kanba S Yagi G Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuro-Psychopharmacol Biol Psychiatry 1994; 18(4): 707-715.
34. Yatham LN Calabrese JR Kusumakar V, et al. Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003; 5: 85-97.
35. Bowden CL Calabrese JR Sachs G, et al. Lamictal 606 Study G: A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypo-manic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4):392-400.
36. Bowden CL Calabrese JR McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481-489.
37. Muzina DJ El-Sayegh S Calabrese JR. Antiepileptic drugs in psychiatry: Focus on randomized controlled trial. Epilepsy Res 2002; 50(1-2): 195-202.
38. Calabrese JR Shelton MD Rapport DJ, et al. Current research on rapid cycling bipolar disorder and its treatment. J Affect Disord 2001; 67: 241-255.
39. Dunner DL Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229-233.
40. Denicoff KD Smith-Jackson EE Disney ER, et al. Comparitive prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
41. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27: 138-145.
42. Calabrese JR Suppes T Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11):841-850.
43. Marcotte D. Use of topiramate, a new antiepileptic as a mood stabalizer. J Affect Disord 1998; 50; 245-251.
44. Calabrese JR Bowden CL Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2): 79-88.
45. Winsberg ME De Golia SG Strong CM, et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67(1-3): 207-212.
46. Post RM Uhde TM Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34.
47. McIntyre RS Mancini DA McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single- blind study. Bipolar Disord 2002; 4(3):207-213.
48. Steinacher L Vandel P Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002; 12(3):255-260.
49. Stuppaeck CH Barnas C Schwitzer J, et al. Carbamazepine in the prophylaxis of major depression: A 5-year follow- up. J Clin Psychiatry 1994; 55(4): 146-150.
50. Kudoh A Ishihara H Matsuki A. Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: A trial of off-on-off-on design. Clin J Pain 1998; 14(1): 61-65.
51. Davis LL Ryan W Bryon A, et al. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol 2000; 20(1): 1S-17S.
52. Normann C Hummel B Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: A placebo- controlled, double-blind study. J Clin Psychiatry 2002; 63(4): 337-344.
53. Pande AC Davidson JR Jefferson JW, et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19(4): 341-348.
54. Lydiard RB Morton WA Emmanuel NP, et al. Preliminary report: Placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacology Bull 1993; 29(2): 183-188.
55. Black DW Wesner R Bowers W, et al. A comparison of flu-voxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50(1): 44-50.
56. Singh L Field MJ Ferris P, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 1996; 127(1): 1-9.
57. Pande AC Pollack MH Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4): 467-471.
58. Post RM Weiss SR Smith M, et al. Kindling versus quenching: Implications for the evolution and treatment of posttraumatic stress disorder. Ann NY Acad Sciences 1997; 821: 285-295.
59. Upper S Davidson JR Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psycho-somatics 1986; 27(12): 849-854.
60. Wolf ME Alavi A Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: Possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23(6): 642-644.
61. Ford N. The use of anticonvulsants in posttraumatic stress disorder: Case study and overview. J Traum Stress 1996; 9(4): 857-863.
62. Viola J Ditzler T Batzer W, et al. Pharmacological management of post-traumatic stress disorder: Clinical summary of a five-year retrospective study, 1990-1995. Military Med 1997; 162(9): 616-619.
63. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52(9): 361-364.
64. Szymanski HV Olympia J. Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991; 148(8): 1086-1087.
65. Clark RD Canive JM Calais LA, et al. Divalproex in posttraumatic stress disorder: An open-label clinical trial. J Trauma Stress 1999; 12(2): 395-401.
66. Petty F Davis LL Nugent AL, et al. Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22(1): 100-101.
67. Hertzberg MA Butterfield ML Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45(9): 1226-1229.
68. Berlant J van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry 2002; 63(1): 15-20.
69. Brannon N Labbate L Huber M. Gabapentin treatment for posttraumatic stress disorder. Canadian J Psychiatry - Rev Canadienne Psychiatrie 2000; 45(1): 84.
70. MacLeod AD. Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996; 16(2): 190-191.
71. Iancu I Rosen Y Moshe K. Antiepileptic drugs in posttraumatic stress disorder. Clinical Neuropharmacology 2002; 25(4): 225-229.
72. Iwata Y Kotani Y Hoshino R, et al. Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000; 61(7): 528-529.
73. Cora-Locatelli G Greenberg BD Martin J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59(9): 480-481.
74. Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD. J Clin Psychiatry 1994; 55(11): 500.
75. Stanford MS Houston RJ Mathias CW, et al. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res 2001; 103(2-3): 193-203.
76. Barratt ES Kent TA Bryant SG, et al. A controlled trial of phenytoin in impulsive aggression. J Clin Psychopharmacol 1991; 11(6): 388-389.
77. Hollander E Dolgoff-Kaspar R Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001; 62(7): 530-534.
78. Lindenmayer JP Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: A critical review. J Clin Psychiatry 2000; 61(2): 123-128.
79. Sival RC Haffmans PM Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: A randomized placebo controlled clinical trial. Intl J Geriatr Psychiatry 2002; 17(6): 579-585.
80. Chambers CA Bain J Rosbuttum R, et al. Carbamazepine in senile dementia and overactivity: A placebo controlled double blind trial. Med Sci 1982; 10: 505-506.
81. Tariot PN Erb R Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54-61.
82. Devarajan S Dursun SM. Aggression in dementia with lamotrigine treatment. Am J Psychiatry 2000; 157(7): 1178.
83. Schachter SC. The evolving place of vagus nerve stimulation therapy. Neurology 2002; 59: S1-S2.
84. Schachter SC. Vagus nerve stimulation therapy summary: Five years after FDA approval. Neurology 2002; 59: S15-S20.
85. Harden CL. The co-morbidity of depression and epilepsy: Epidemiology, etiology, and treatment. Neurology 2002; 59: S48-S55.
86. Renfroe JB Wheless JW. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 2002; 59: S21-S25.
87. Henry TR. Therapeutic mechanisms of vagus nerve stimulation. Neurology 2002; 59: S3-S14.
88. Harden CL Pulver MC Ravdin LD, et al. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav 2000; 1: 93-99.
89. Krahl SE Clark KB Smith DC, et al. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998; 39: 709-714.
90. Sackeim HA Rush AJ George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: Efficacy, side-efects and predictors of outcome. Neuropsychopharmacology 2001; 25: 713-728.
91. Marangell LB Rush AJ George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: One year outcomes. Biol Psychiatry 2002; 51: 280-287.
92. George MS Nahas Z Bohning DE, et al. Vagus nerve stimulation therapy: A research update. Neurology 2002; 59: S56-S61.
93. McDonald WM Greenberg BD. Electroconvulsive therapy in the treatment of neuropsychiatry conditions and transcranial magnetic stimulation as a pathophysiological probe in neuropsychiatry. Depress Anxiety 2000; 12: 135-143.
94. Lam RW Zis AP Goumeniouk AD. Somatic treatments for bipolar disorder. In: Yatham LN, Kusumaker V, Kutcher SP, (eds). Bipolar Disorder: A Clinician's Guide to Biological Treatments. New York: Brunner-Routledge; 2002: 241-254.
95. Gershon AA Danon PN Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003; 160: 835-845.
96. Theodore WH. Transcranial magnetic stimulation in epilepsy. Epilepsy Behav 2001; 2: S36-S40.
97. George MS Wassermann EM Williams WA Callahan A Ketter TA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuro Report 1995; 6: 1853-1856.
98. George MS Nahas Z Kozel FA, et al. Mechanisms and the current state of transcranial magnetic stimulation. CNS Spectrums 2003; 8: 496-514.
99. Martin JLR Barbanoj MJ Schlaepfer TE, et al. Repetitive transcranial magnetic stimulation for the treatment of depression. Br J Psychiatry 2003; 182: 480-491.
100. Grunhaus L Dannon PN Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: An open study. Biol Psychiatry 2000; 47: 314-324.
101. Grunhaus L Schreiber S Dolberg OT, et al. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2000; 47: 314-324.
102. Nahas Z Kozel FA Li X, et al. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: A pilot study of acute safety and efficacy. Bipolar Disord 2003; 5: 40-47.
103. Kaptsan A Yaroslavsky Y Applebaum J, et al. Right prefrontal TMS versus sham treatment of mania: A controlled study. Bipolar Disord 2003; 5: 36-39.